Risk Disclosure Impact for Alzheimer's Disease
(WeSHARE Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What makes this Alzheimer's disease treatment unique?
This treatment is unique because it focuses on disclosing genetic and biomarker information to assess Alzheimer's disease risk, which is not commonly done in standard treatments. It aims to help individuals understand their risk and make informed decisions, despite the challenges and controversies surrounding the predictive value and psychological impact of such information.12345
What is the purpose of this trial?
This trial provides participants with a report predicting their future risk of developing Alzheimer’s disease. It targets people without memory or thinking problems in an aging study. The prediction is made using genetic data, brain scans, blood tests, and demographic information.
Research Team
Sarah Hartz, MD
Principal Investigator
Washington University School of Medicine
Eligibility Criteria
This trial is for healthy individuals aged 65 or older who are part of the Knight Alzheimer Disease Research Center and have been deemed cognitively normal. They must have recent brain scans or blood tests, genetic research results including APOE status, and be open to being contacted for further research.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Educational Material Review and Informed Consent
Participants review educational materials and sign the informed consent document
Disclosure of Research Results
Participants receive their research results either two weeks or one year after informed consent, depending on their assigned arm
Follow-up
Participants are monitored for psychological and behavioral responses to the disclosure of research results
Treatment Details
Interventions
- Arm A
- Arm B
- Arm C
- Arm D
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor